-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoporosis-vibration-therapy_disposition-comments.pdf
November 15, 2011 - Section Comment Response
Peer Reviewer #1 Methods The inclusion and exclusion criteria are explicitly described
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/ankyloglossia_executive.pdf
May 01, 2015 - Laser frenotomy or
frenulotomy has also been described, and proponents argue
that its use is more exact … for
Healthcare Research and Quality standard of “good,”
“fair,” and “poor” quality designations, as described … Bleeding was typically described as minor and
limited. Reoperation was noted in seven studies. … Few
studies described the specific methods they used to collect
harms data. … assessment
of breastfeeding difficulty and diagnostic criteria for
ankyloglossia were not universally described
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/smoking-pregnancy-infants_executive.pdf
February 01, 2014 - adjustment of the data and results
• Studies targeting women who smoke and meet the population criteria described … Data Synthesis
To synthesize the data, we first divided the studies into
broad categories and described … Data for Key Questions 2, 3, and 5 were described
qualitatively. … effectiveness
of intervention components using the meta-analysis
(Table E) and using the approach described … As
described earlier, incentives had the highest independent
effect, but given that the statistical
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/dementia-agitation-aggression_research-protocol.pdf
November 13, 2014 - Agitation is often described as “excessive motor activity with a feeling of
inner tension and characterized … such as
pacing, wandering, aggression, shouting and nighttime disturbance.”16 Aggression is commonly
described … the review based on the PICOTS framework outlined
above and the study-specific inclusion criteria described … processes, narrow eligibility criteria, and patient and intervention characteristics different
than those described … dementia.42 These
applicability issues are present in the synthesis frameworks and sensitivity analyses
described
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/breast-biopsy_disposition-comments.pdf
March 11, 2010 - The different types of
core-needle biopsy are described later; the … Introduction DCIS classifications use histologic grade, so the statement that only
invasive tumors are described … Section Comment Response
Introduction The process that breast biopsy works within needs to be better
described … The searches for literature addressing all questions
are exactly as described. … supplemented with expert opinion (e.g., the
Technical Expert Panel and review articles
identified by the described
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/single-group-studies_white-paper.pdf
January 01, 2013 - single group studies to resolve clinical questions that are inherently
comparative in nature should be described … A number of study types would be included in this
category, including investigations described as ― … harms 0 (0)
Quantitatively combined single group studies with comparative studies for harms 0 (0)
Described … of the effects from single group studies adjacent to the 5 (24)
syntheses of comparative studies
Described … Only about half of these CERs (9/19, 47%) described these harms data in the
context of data from comparative
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/liver-cancer-therapy_research-protocol.pdf
November 28, 2012 - o Were inclusion/exclusion criteria clearly described? … o Were baseline prognostic characteristics clearly described and groups shown to be
comparable? … characteristics proposed by Carey and Boden,46 as follows:
o Clearly defined question
o Well-described … study population
o Well-described intervention
o Use of validated outcome measures
o Appropriate … statistical analyses
o Well-described results
o Discussion and conclusion supported by data
o
-
effectivehealthcare.ahrq.gov/sites/default/files/prostatic-hyperplasia-medications_disposition-comments.pdf
May 26, 2016 - Peer Reviewer
#1
Methods In general, methods described and used in this report are typical for systematic … This is
mentioned in the text and described in detail
in the appendices for each study. … We described AUR as it was described in
the original trial. … TEP Reviewer
#3
Discussion/
Conclusion
The discussion is satisfactory, Limitations are well-described … This is
described in the appendix overview table for
that section.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/nonpharm-treatment-chronic-pain-protocol.pdf
December 11, 2018 - evidence to address gaps in
evidence identified in the previous report and thus some of the needs described … exclusion of studies for the systematic review will
be based on the Key Questions and are briefly described … The strength of the evidence may be downgraded based on the limitations
described above. … effect, presence of dose-response
relationship or existence of plausible unmeasured confounders) as described … review of the public comments, and input from Key Informants and the
Technical Expert Panel (TEP) as described
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/alcohol-misuse_research-protocol.pdf
April 28, 2010 - with a
primary care-type relationship that may be applicable to
traditional primary care settings as described … The
steps that we will take to accomplish the literature review are described below. … Rather, since our review has some differences in scope (described above
on page 5), we will search … Appropriateness will be determined by the same methods described above.
Table 2. … As described above, all results will be tracked in an EndNote
database.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/angina-heart-attack-treatments_disposition-comments.pdf
January 01, 2014 - The objective is described in the Scope section of
the Executive Summary. … The
methods for inclusion are clearly described.
Thank you. … I would suggest that the
differences just be described and avoid value terms when
possible. … The one study is not described as
RCT or observational as is done in all the other sections. … The explanation and how it
was handled was well-described for the reader and seemed
appropriate.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/organization-cancer-care-disposition-comments.pdf
June 20, 2023 - Also described utility
of one specific theory
25 Peer Reviewer #1 Guiding
Questions
The guiding … We appreciate
the comment.
30 Peer Reviewer #1 Methods Authors clearly and concisely described the … discussing Key Informant engagement,
the authors specified the number and type of informants, as well as
described … organization,
financing, and
delivery of health
care in the US.
35 Peer Reviewer #4 Methods Well described … with Key Informants: Not sure you need the first
sentence since it is a method, and has already been described
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-report-web-interactive-presentation.pdf
September 01, 2019 - Conclusions: In sum, we described a foray into an alternative view of a systematic review that
complements … In sum, we described a foray into an alternative view of a systematic review that
complements a static
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/people-with-disabilities-protocol.pdf
January 16, 2024 - criteria for inclusion and exclusion of individual studies are based on the Key Questions and
PICOTS described … the ICF.39,40
We will construct evidence tables with the relevant data from included studies (as described … Questions, we will conduct additional sub-group analyses of specific populations of interest (as
described … We will use the approach described in the AHRQ Methods Guide.49 To ensure reliability and validity of … Applicability of Evidence
We will assess applicability according to the approach described in the AHRQ
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/c-diff-infections_disposition-comments.pdf
March 01, 2012 - Strains that produce toxin A and toxin B and strains that
produce only toxin B have been described. … Strains that produce only
toxin A have not been described, but this is not clear from the current
wording … The described program is still ongoing with the outcome
sustained.
See response below. … Also the risk rates described as very small,
moderate and substantial are not well defined or supported … In the study by Surawicz (Clin Infect Dis
2001), the sample is described as patients
with recurrent
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-212-urinary-incontinence-disposition-comments.pdf
August 08, 2018 - This
is now clearly described in the methodological appendix that
describes the analysis. … Too detailed for report, but described in full in the new
appendix. … Methods Peer Reviewer #6 The Methods were well described and
understandable. … Inclusion/exclusion criteria well
described. Search strategies and definitions
well described. … It is
the most costly and cumbersome of the
biofeedback options described in this
document.
-
effectivehealthcare.ahrq.gov/sites/default/files/c-difficile-update_disposition-comments.pdf
March 29, 2016 - Commentator &
Affiliation Section Comment Response
Peer Reviewer #3 Methods The methods described … The search
strategy listed is logical and clearly described. … The characteristics of the
studies are clearly described. … Similarly, rifaximin is described
and used as an adjunct therapy
(albeit one that is an antibiotic) … Limitations of the review/studies are
clearly & adequately described.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cancer-survivor-care-transition_disposition-comments.pdf
March 18, 2014 - There are a number of
concerns with the report, as described below. … This information is described in Appendix A. … This information is described in Appendix A. … The outcomes must have been explicitly described as
such in the study. … The other predictors described by the reviewer are noted
in the text.
-
effectivehealthcare.ahrq.gov/sites/default/files/cer-240-acute-pain-revised-comments.pdf
December 29, 2020 - We included studies that met pre-
defined inclusion criteria as
described in the Methods. … The limitations of the
notice are described and
evidence rated using AHRQ
methods. … Harms of opioids are
well-described in the report. … Potential
harms of opioids are described in
the Background section. … Chronic pain was
excluded, as described in the
methods.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/mgmt-hnhc-patients-protocol.pdf
November 07, 2019 - Care coordination is a central component, particularly
during health care setting transitions (as described … Within that population, we will present the patterns of persistent health
care use and costs described … exclusion table (continued)
PICOTS Inclusion Exclusion
Outcomes KQ 1: Population characteristics described … We will identify all eligible studies using the same criteria described above. … As described above, all results will be tracked in
an EndNote database.
14
For the realist